The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.

Authors

Michael J Vido, Department of Cancer Biology, Thomas Jefferson University; Sidney Kimmel Cancer Center, Thomas Jefferson UniversityFollow
A E Aplin, Department of Cancer Biology, Thomas Jefferson University; Sidney Kimmel Cancer Center, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-14-2015

Comments

This article has been peer reviewed. It was published in: Journal of Investigative Dermatology.

Volume 135, Issue 10, 14 October 2015, Pages 2355-2357.

The published version is available at DOI: 10.1038/jid.2015.239

Copyright © 2015 The Authors

Abstract

The novel Hsp90 inhibitor XL888 is undergoing clinical investigation for use in conjunction with the rapidly accelerated fibrosarcoma (RAF) kinase inhibitor vemurafenib to treat unresectable melanoma. The addition of XL888 to current regimens may serve an additional purpose by blocking the RAF inhibitor paradox. Such activity could reduce adverse events in patients and provide a biomarker for the successful inhibition of Hsp90 target proteins.

Recommended Citation

Vido, Michael J and Aplin, A E, "The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox." (2015). Department of Cancer Biology Faculty Papers. Paper 85.
https://jdc.jefferson.edu/cbfp/85

PubMed ID

26358385